Navigation Links
Drop Patent Petition, Activists Ask Novartis

Seeking to keep the price of a cancer drug affordable for masses, activists from several countries Monday gathered here and asked Swiss pharmaceutical major Novartis// to withdraw its case against the Indian government that has not granted patent to its anti-cancer medicine.

"India produces affordable medicines that help millions of people both here and in many other developing countries. A patent grant to Novartis on Gleevec will certainly make cancer medicine unaffordable for the poor," said Amit Sengupta, joint convenor of the PEOPLE'S Health Movement.

"While a generic drug for cancer costs Rs.8,000 for one month of treatment, Gleevec costs Rs.120,000. If Novartis gets the patent, then generic drugs will not be available in market," Sengupta told reporters.

In May 2006, Novartis had filed two cases against the government of India and the Cancer Patients Aid Association (CPAA) challenging the rejection of its patent application under the Indian Patent Law.

The company's application for a patent on Gleevec was opposed by the CPAA and subsequently rejected by the Chennai patent office in January 2006.

The application was rejected as it claimed Gleevec to be only a new form of an old drug and not an invention.

Unni Karunakara, medical director of the Medicins Sans Frontieres, a Netherlands-headquartered organisation, said that India is the main supplier of essential medicines for developing countries. Sixty-seven percent of the medicines produced in India are exported to developing countries, he said.

"A patent grant to Novartis will not only affect people in India but also millions of people in developing countries. It will set a wrong precedent for frivolous applicants to get patent by just tinkering molecules. Innovations of drugs will become difficult," Karunakara said.

"General public cannot afford the second line drugs as their cost will increase between seven to 30 times, " he added.

Michel Lotrowski, a Brazilian activist, said Novartis was embarking on sheer profiteering without even thinking of public health conditions.

K.M. Gopakumar, a member of the Centre for Trade and Development, said Novartis had challenged Section 3-D of the Indian Patent Act that dismisses frivolous patent applications as incongruous.

"Does the multinational want to say that the Indian government should frame law keeping in mind Novartis' profit motive? Can't we stop frivolous patent applications from seeing light?" Gopakumar asked.

Source-IANS
'"/>




Related medicine news :

1. Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations
2. HIV Patients Opposes Patenting Of AIDS Drug
3. Provigil Patent Extension Accorded To Cephalon
4. AIDS Sufferers Protest against Proposed Patent for Tenofovir
5. POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
6. Venus Remedies Files 5th International Patent Application
7. US Court Rules Against Lupin in Ramipril Patent Case
8. Patent for Seminal RNAi innovation Cleared in Australia
9. Canada: On Popular Demand, Tamiflu finds a Berth in the Directory of Patent Drugs
10. Compellis Pharmaceuticals Gets Patent for Obesity-Fighting Nasal Spray CP404
11. A Patented Device for Rapid Diagnosis of Diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/23/2017)... ... January 23, 2017 , ... The Masters of Science ... evaluation leaders with decades of experience who remain current practitioners in the field. ... system, there is a renewed demand for versatile, data-driven leadership.The American University’s MS ...
(Date:1/23/2017)... ... January 23, 2017 , ... Moisture measurement is a ... method is paramount to success. Selecting an inappropriate measurement method can cause costly ... use the same equipment. Rare or expensive substances are wasted and production may ...
(Date:1/23/2017)... ... January 23, 2017 , ... Gynecology Associates of ... gynecological services for women of all ages. The staff of Gynecology ... of reproductive services from routine health screenings to diagnosing and treating female concerns ...
(Date:1/23/2017)... ... ... “Some Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring the ... of published author, Rev. Dr. Robert W. Thomas, the third of seven siblings. He ... nineteen, a pastor for over fifteen years. He is a graduate of N.C. College ...
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals and ... a simple test will take days to arrive to the end customer, having to ... access to their lab tests, bypassing the cost and delay of traditional means. Now ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Jan 23, 2017 Research and Markets has announced ... Trends - Product - Forecast to 2025" report to their offering. ... Report Highlights: ... market trends to identify the investment opportunities Market forecasts ... Key market trends across the business segments, Regions and Countries ...
(Date:1/23/2017)... Jan. 23, 2017  Using Astute Medical,s ... risk for acute kidney injury (AKI) after open-heart ... care guidelines significantly improved outcomes by ... more than 33 percent, according to a ... Intensive Care Medicine. Experience ...
(Date:1/23/2017)... January 23, 2017 Ahead of today,s trading ... how they have fared at the close: Kite Pharma Inc. (NASDAQ: ... OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... were relative laggards on Friday, January 20 th , 2017, down ... research reports on these stocks now at: ...
Breaking Medicine Technology: